Spero's TB program first licensing deal for Gates Medical Research Institute

A partnership to develop Spero's Phase I compound for tuberculosis is the first licensing deal announced by Gates

Read the full 185 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE